Straits Times Index
3,410.81 -29.07 (-0.85%) Nikkei
40,912.37 -1.28 (-0.00%) Hang Seng
17,799.61 -228.67 (-1.27%) FTSE 100
8,203.93 -37.33 (-0.45%) Bitcoin USD
57,972.23 +1,784.30 (+3.18%) CMC Crypto 200
1,199.16 -9.54 (-0.79%)
Coeptis Therapeutics Holdings, Inc. (COEP)
After hours:
| Previous close | 0.2800 |
| Open | 0.2651 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.2651 - 0.2938 |
| 52-week range | 0.2300 - 1.5800 |
| Volume | |
| Avg. volume | 508,622 |
| Market cap | 10.43M |
| Beta (5Y monthly) | -0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.00 |
PR NewswireCoeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering
Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce that it has closed on $4.3 million in a financing led by CJC Investment Trust, an entity controlled by board member Christopher Calise.
- PR Newswire
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting
Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that Dr. Colleen Delaney will be attending and presenting at the Allogeneic Cell Therapies Summit 6th Annual Meeting from June 10-12 in Boston, MA.
- PR Newswire
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024
Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced today that the Company has been selected for an oral presentation of the abstract titled Developing A First-In-Class Universal Allogeneic Snap-Car NK Cell Therapy at the International Society for Cell & Gene Therapy 2024, being held May 28th to June 1st in Vancouver, Canada.
